For research purposes only — not for human consumption — 18+ only
Other
PT-141 10mg
$60.00
Bremelanotide. Melanocortin receptor agonist studied for sexual dysfunction research via CNS pathways.
Use the peptide calculator to determine exact reconstitution volumes and dosing schedules for your research protocol.
Open Peptide Calculator ↗PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide melanocortin receptor agonist derived from Melanotan II through removal of the C-terminal amide group and other structural refinements designed to improve selectivity and reduce unwanted melanogenic effects. PT-141 was specifically developed to act via central nervous system pathways for sexual dysfunction research. It received FDA approval in 2019 under the brand name Vyleesi for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women — making it one of the few research peptides to achieve regulatory approval.
Molecular Data
Sequence: Cyclo(Nle4, D-Phe7)-α-MSH(4-10) OH | Molecular Formula: C50H68N14O10 | Molecular Weight: 1025.17 g/mol | CAS Number: 189691-06-3
Central Nervous System Mechanism
Unlike PDE5 inhibitors (sildenafil, tadalafil) which act peripherally on vascular smooth muscle, PT-141 acts centrally through melanocortin receptors in the hypothalamus and limbic system. MC4R agonism in the medial preoptic area activates dopaminergic pathways in the mesolimbic system — the same reward and motivation circuitry engaged by natural sexual arousal. This central mechanism means PT-141 addresses sexual motivation and desire rather than peripheral vascular engorgement, representing a fundamentally different research approach to sexual dysfunction.
MC3R and MC4R Pharmacology
PT-141 demonstrates agonist activity primarily at MC3R and MC4R. MC4R is the principal receptor mediating its effects on sexual behaviour, as demonstrated by the absence of these effects in MC4R knockout mouse models. MC3R co-activation contributes to energy homeostasis effects and may modulate the intensity of MC4R-mediated responses. The relative contribution of each receptor subtype remains an active area of pharmacological investigation.
FDA Approval and Clinical Evidence
The FDA approval of Bremelanotide (Vyleesi) for HSDD provides clinical validation unusual for a research peptide. Phase III clinical trials demonstrated statistically significant improvements in desire and reductions in distress related to low sexual desire in premenopausal women. The mechanism of action through central melanocortin pathways was confirmed as distinct from and complementary to existing peripheral treatments.
Broader Melanocortin Research
PT-141's well-characterised pharmacology and FDA approval make it a valuable research tool for investigating melanocortin receptor pharmacology more broadly. Its use in research has contributed to understanding of MC3R/MC4R signalling in appetite regulation, energy homeostasis, and the neurological circuits mediating motivational behaviour — applications that extend well beyond its approved indication.
Future Research
Research continues into melanocortin receptor pharmacology, male sexual dysfunction applications, energy homeostasis, and the neurological circuits governing motivation and reward. The clinical validation provided by FDA approval supports broader research programme development.
Reviews
There are no reviews yet.